Havrix Junior

Havrix Junior is a prescription injectable vaccine that contains an inactivated hepatitis A virus antigen adsorbed on aluminium hydroxide. The product is supplied as an intramuscular solution; the specific strength is not disclosed in the public labeling. Developed for the European market, Havrix Junior belongs to the vaccine drug class and is intended to stimulate protective immunity against hepatitis A infection in children and adolescents.

Havrix Junior is indicated for the prevention of hepatitis A infection in individuals for whom active immunization is appropriate.

- Primary prophylaxis against hepatitis A in children aged 12 months and older. - Use in outbreak settings to quickly establish herd immunity. - Administration as part of a two‑dose schedule, typically spaced 6–12 months apart. - May be given to travelers to regions with intermediate or high hepatitis A endemicity. - Can be used in combination with other routine childhood vaccines when schedule permits.

The safety profile of Havrix Junior reflects typical vaccine reactions, most of which are mild and self‑limiting.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever within 24–48 hours after vaccination. - Mild fatigue or irritability, especially in younger children. - Tenderness or mild muscle ache near the injection site. - Mild headache or malaise within the first day. - Persistent high fever (>39 °C) lasting more than 48 hours, or severe systemic illness.

Serious: - Anaphylactic reaction presenting with hives, airway swelling, or hypotension. - Guillain‑Barré syndrome, a rare neurologic disorder reported after vaccination. - Seizure activity (rare) occurring shortly after vaccination. - Severe allergic reaction manifesting as angioedema or bronchospasm. - Persistent high fever (>39 °C) lasting more than 48 hours, or severe systemic illness. - Seizure activity (rare) occurring shortly after vaccination.

Prior to administering Havrix Junior, healthcare professionals should evaluate several precautionary factors to ensure safe use.

- Confirm that the individual has not previously experienced a severe allergic reaction to any hepatitis A vaccine or its components. - Defer vaccination in persons with a known hypersensitivity to aluminium salts. - Postpone the dose in children with acute moderate or severe illness until recovery. - Assess immunocompromised status, as response to the vaccine may be reduced. - Discuss pregnancy and breastfeeding status; data are limited, and vaccination should follow clinical judgment. - Record any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior has a limited interaction profile, but certain concomitant therapies may require attention.

Avoid: - Concurrent administration with live attenuated vaccines is generally avoided within a 4‑week window to prevent immune interference. - Do not give Havrix Junior to individuals receiving immunoglobulin therapy intended for passive hepatitis A prophylaxis, as it may neutralize the vaccine antigen.

Use with caution: - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy) may diminish the antibody response; consider timing of vaccination. - Antipyretics such as acetaminophen can be used to manage post‑vaccination fever, but routine prophylactic use may blunt the immune response. - In patients with chronic liver disease, vaccination is recommended, but monitoring for adverse reactions is advised.